Compare Eversource Energy (D/B/A) Common Stock (ES) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $66.67 (market cap $25.11B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.75 (market cap $2.51B). The key difference: Eversource Energy (D/B/A) Common Stock is far larger — about 10× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.72% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and SELLAS Life Sciences Group Inc. Common Stock for 0 Days on average.
| ES | SLS | |
|---|---|---|
Market Cap | $25.11B | $2.51B |
Volume | 3,164,400 | 6,359,048 |
Sector | Utilities | Health |
52-Week High | $76.21 | $15.46 |
52-Week Low | $63.28 | $1.39 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $55.18B | $2.37B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.
The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
